With a short percentage of shares outstanding of 2.91%, Teva Pharmaceutical Industries Limited (NYSE:TEVA) is among the 7 Best Pet Care Stocks to Buy for Consistent Recurring Revenue.
On June 8, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced new clinical and real-world findings supporting the effectiveness of Austedo and Austedo XR in the treatment of tardive dyskinesia. Data from the real-world IMPACT-TD study showed that patients with mild symptoms experienced measurable reductions in involuntary movement scores after three months of therapy, accompanied by improvements in their ability to perform everyday activities. The company also reported results from the three-year RIM-TD study, which demonstrated that more than half of patients responded to treatment by week 15, while an additional 23% achieved clinically meaningful improvement after that point. Management emphasized that these findings reinforce Teva’s commitment to advancing the diagnosis, treatment, and long-term management of tardive dyskinesia through evidence-based research and innovation.
Earlier, on June 4, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced the European launch of Ahzantive, a biosimilar version of Eylea, marking another step in the expansion of its biosimilars business. The company began rolling out Ahzantive pre-filled syringes across several major European markets, including France, Germany, Spain, and the Netherlands. The launch broadens Teva’s biosimilar portfolio and enhances its position in the ophthalmology market, where healthcare systems continue to seek more affordable treatment alternatives. By expanding access to lower-cost therapies, Teva aims to strengthen its competitive presence in a growing segment of the pharmaceutical industry while diversifying its revenue opportunities.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is a global pharmaceutical company headquartered in Israel and founded in 1901. The company specializes in generic medicines, biosimilars, and specialty pharmaceuticals, serving patients across numerous therapeutic areas worldwide. Although primarily focused on human healthcare, Teva’s products also influence animal health, as many of its approved medications and antibiotics are commonly prescribed by veterinarians to treat a variety of conditions in companion animals and livestock.
While we acknowledge the risk and potential of TEVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TEVA and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Most Overvalued Quantum Computing Stocks According to Short Sellers and 7 Best Longevity and Anti-Aging Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
